CD8+ CD19-CAR T细胞输注后优先扩增及疾病负荷对儿童B-ALL结局的影响
这项1/2期临床研究评估了本机构自体CD19-CAR T细胞产品在复发/难治性儿童B-ALL中的表现,报告1期12例受试者结果:治疗耐受良好,细胞因子释放综合征任一等级6例、神经毒性任一等级3例,9/12例(75%)达骨髓微小残留病阴性完全缓解;输注前高疾病负荷(≥40%形态学原始细胞)与副作用增加和缓解率降低相关,但与CD19-CAR T细胞扩增无关;输注后CD8+ CAR T细胞较CD4+ CAR T细胞具有增殖优势,峰值扩增时呈效应记忆表型并可见抗原驱动分化证据;后续接受异基因造血细胞移植的患者获得持续持久缓解。
要点
- 1期12例复发/难治性儿童B-ALL中,9/12例(75%)达骨髓微小残留病阴性完全缓解。
- 细胞因子释放综合征任一等级6例、神经毒性任一等级3例,治疗耐受良好。
- 输注前高疾病负荷(≥40%形态学原始细胞)与副作用增加和缓解率降低相关。
核心结论
- 本机构CD19-CAR T细胞产品的初步评估显示安全性和有效性,并突出输注前疾病负荷对结局的影响。
研究设计与样本
- 1/2期临床研究,评估本机构自体CD19-CAR T细胞产品在复发/难治性儿童B-ALL患者中的表现,此处报告1期受试者(n=12)的结果。
- 试验注册号为NCT03573700。
主要发现
- 治疗耐受良好,细胞因子释放综合征任一等级6例、神经毒性任一等级3例。
- 9/12例(75%)达骨髓微小残留病阴性完全缓解。
- 输注前高疾病负荷(≥40%形态学原始细胞)与副作用增加和缓解率降低相关,但与CD19-CAR T细胞扩增无关。
- 输注后CD8+ CAR T细胞较CD4+ CAR T细胞具有增殖优势,峰值扩增时呈效应记忆表型并可见抗原驱动分化证据。
- 后续接受异基因造血细胞移植的患者获得持续持久缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T cells expressing CD19-specific chimeric antigen receptors (CD19-CARs) have potent antileukemia activity in pediatric and adult patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL). However, not all patients achieve a complete response (CR), and a significant percentage relapse after CD19-CAR T-cell therapy due to T-cell intrinsic and/or extrinsic mechanisms. Thus, there is a need to evaluate new CD19-CAR T-cell products in patients to improve efficacy. We developed a phase 1/2 clinical study to evaluate an institutional autologous CD19-CAR T-cell product in pediatric patients with relapsed/refractory B-ALL. Here we report the outcome of the phase 1 study participants (n = 12). Treatment was well tolerated, with a low incidence of both cytokine release syndrome (any grade, n = 6) and neurotoxicity (any grade, n = 3). Nine out of 12 patients (75%) achieved a minimal residual disease-negative CR in the bone marrow (BM). High disease burden (≥40% morphologic blasts) before CAR T-cell infusion correlated with increased side effects and lower response rate, but not with CD19-CAR T-cell expansion. After infusion, CD8+ CAR T cells had a proliferative advantage over CD4+ CAR T cells and at peak expansion, had an effector memory phenotype with evidence of antigen-driven differentiation. Patients that proceeded to allogeneic hematopoietic cell transplantation (AlloHCT) had sustained, durable responses. In summary, the initial evaluation of our institutional CD19-CAR T-cell product demonstrates safety and efficacy while highlighting the impact of pre-infusion disease burden on outcomes. This trial was registered at www.clinicaltrials.gov as #NCT03573700.
引用
- Talleur AC, Qudeimat A, Métais JY, et al. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Adv. 2022. PMID: 35446934. doi:10.1182/bloodadvances.2021006293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。